Abstract 4146993: Anthracycline-based Chemotherapy in A Patient with Breast Cancer and Left-Ventricular Hypertrabeculationdoi:10.1161/circ.150.suppl_1.4146993Cardio-oncologyIntroduction:Anthracyclines (AC), a class of chemotherapeutic drugs, are used to treat various cancers, including breast cancer (BC)....
CONCLUSION: The use of anthracycline-based chemotherapy and reduction of immunosuppression as first-line treatment in adults with monomorphic PTLD is well tolerated and achieves sustained complete remission in around 70% of patients with a low risk of graft loss. 展开 ...
3 Anthracycline-based chemotherapy programs, predominantly cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOEP (CHOP + etoposide), are widely used in the upfront treatment of PTCLs, despite suboptimal results.4,5,6 Neither intensified/escalated chemotherapeutic approaches7,8 ...
Conventional anthracycline- based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012;51(4):550-554.Constantinidou A, Jones RL, Olmos D, Thway K, Fisher C, Al-Muderis O, et al: Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous ...
Rituximab added to standard anthracycline-based chemotherapy demonstrated significant improvements in progression-free survival as well as overall survival as treatment of patients with follicular lymphoma, according to 35-year follow-up results of patie
Adjuvant anthracycline-based chemotherapy has been shown to improve disease-free survival (DFS) rates and overall survival (OS) rates in women with early-stage breast cancer, irrespective of estrogen receptor, progesterone receptor, and HER2 status. Retrospective studies using banked tumor samples from...
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: r... Neoadjuvant trials conducted using a double HER2 blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy ...
Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer . Acta Oncol 2005 ; 44 : 458 - 466 .↵ Arriagada R , Spielmann M , Koscielny S , et al . Results of two randomized trials evaluating adjuvant anthracycline-based ...
At data cutoff (April 3, 2020), median follow-up was 20·6 months (IQR 8·7–24·9) in the atezolizumab plus chemotherapy group and 19·8 months (8·1–24·5) in the placebo plus chemotherapy group. Pathological complete response was documented in 95 (58%, 95% CI 50–65) patients...
All rights reserved 0893-3952/12 $32.00 The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer Caroline M Woolston1, Lei Zhang1, Sarah J Storr1, Ahmad Al-Attar2, Mohamed Shehata2, Ian O Ellis3, Stephen Y...